CDTTW — CDT Equity Inc.

CDTTWCDT Equity Inc.

NAS · US · Healthcare · Biotechnology · cdtequity.com

0.0150USD+82.93%Mkt Cap: —P/E: —Last update: 2026-06-01

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials …

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

40.10BUSDP/E 75.3

RVMD

Revolution Medicines, Inc.

Indicators:|

Key Statistics

Company

Market Cap—

Enterprise Value—

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-39.22M USD

Revenue/Share—

Last Price0.0150 USD

Fiscal Year End—

MR Quarter—

Employees4

CountryUS

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-0.00

EPS (TTM)—

EPS (Forward)—

52W Range

0.006663% of range0.0200

52W High0.0200 USD

52W Low0.0066 USD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE547.06%

ROA-694.23%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-15.55M USD

CapEx (TTM)2.40M USD

FCF Margin—

FCF Yield—

Net Debt-734.00K USD

Net Debt/EBITDA0.03

Balance Sheet

Debt/Equity-0.11

Current Ratio0.34

Quick Ratio0.12

Book Value/Sh-77.8160 USD

Cash/Share0.3110 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.—

Float2.29M

Insiders—

Institutions—

Technical

SMA 50—

SMA 200—

Beta1.57

S&P 52W Chg27.94%

Avg Vol (30d)3.22K

Avg Vol (10d)—

Technical Indicators

RSI (14)99.5

MACD0.0001

MACD Signal0.0000

MACD Hist.+0.0001

BB Upper0.0074 USD

BB Middle0.0067 USD

BB Lower0.0060 USD

BB Width21.42%

ATR (14)0.0010 USD

Vol Ratio (20d)—